Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026
Alpha Tau reports 100% local disease control with Alpha DaRT device in heavily pre-treated pancreatic cancer patients with favorable safety profile.
MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug
MacroGenics expands its ZYNYZ royalty purchase agreement with Sagard Healthcare Partners, providing additional funding for the cancer immunotherapy drug.
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
Celcuity's VIKTORIA-1 Phase 3 trial shows clinically meaningful progression-free survival improvement with gedatolisib in PIK3CA mutant patients.
FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
Guardant Health receives FDA approval for blood-based companion diagnostic to identify patients eligible for VEPPANU treatment in advanced breast cancer with ESR1 mutations.
Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns
The U.S. Food and Drug Administration (FDA) has granted approval for palazestrant, a novel breast cancer treatment developed by Pfizer and Arvinas. This decision comes despite some concerns raised about the drug's clinical trial data, marking a significant development in breast cancer therapy.
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial enrollment, marking a key milestone in synthetic lethality cancer treatment.
Cairn Surgical's Breast Cancer Locator System Meets Primary Endpoint in Pivotal Trial, Reduces Positive Margin Rates
Cairn Surgical announces positive pivotal trial results for its Breast Cancer Locator System, showing reduced positive margin rates compared to conventional wire localization.
Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
Atara Biotherapeutics' EBVALLO cancer therapy receives FDA Complete Response Letter, delaying approval as company faces securities class action lawsuit deadline May 22, 2026.
Arvinas Receives FDA Approval for VEPPANU (Vepdegestrant), First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas announces FDA approval of VEPPANU, the first PROTAC protein degrader for ESR1-mutated, ER+/HER2- advanced breast cancer treatment.
Summit Therapeutics Ivonescimab Shows Overall Survival Benefit in Lung Cancer, ASCO 2026 Plenary Data Expected
Summit Therapeutics reports overall survival data for ivonescimab in first-line squamous NSCLC will be featured at ASCO 2026 plenary session as late-breaking abstract.
Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference
Mabwell announces presentation of clinical trial data for 9MW2821, a novel Nectin-4 targeting ADC for cervical cancer treatment at ESMO GC 2026.